Genetic implications in the metabolism and toxicity of mycotoxins

G E Neal1

  • 1MRC Toxicology Unit, University of Leicester, UK.

Toxicology Letters
|December 1, 1995
PubMed

Insights

Metabolic enzymes control how animals respond to mycotoxins like aflatoxins and ochratoxins. Understanding enzyme expression is key to developing strategies for preventing mycotoxin toxicity.

Area of Science:

  • Toxicology
  • Biochemistry
  • Genetics

Background:

  • Metabolic activation and detoxification are critical in determining animal responses to mycotoxin exposure.
  • Enzyme expression, both constitutive and inducible, significantly influences acute and chronic toxicities induced by mycotoxins.

Purpose of the Study:

  • To review the role of metabolic factors in toxic responses to aflatoxins and ochratoxins.
  • To highlight the importance of enzyme expression control in mycotoxin toxicity and chemoprotection.

Main Methods:

  • Review of existing literature on aflatoxin and ochratoxin metabolism.
  • Analysis of enzyme expression control mechanisms, including genetic regulation.

Main Results:

  • Secondary, conjugating metabolism is increasingly recognized as important for aflatoxin detoxification.
  • Specific control of enzyme expression via gene sequences in the 5' region is evident for aflatoxins.
  • Genetic control mechanisms for enzymes involved in ochratoxin nephrotoxicity are likely to be revealed by future studies.

Conclusions:

  • Understanding the genetic control of metabolic enzymes is crucial for developing effective chemoprotective strategies against mycotoxins.
  • Further research into ochratoxin metabolism and its genetic regulation is warranted.

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...